-
Apr 10, 2021
F-star Therapeutics Shows Differentiation of FS222 in 2021 AACR Poster -
Apr 01, 2021
F-star Therapeutics Announces Third Option Exercised by Merck KGaA, Darmstadt, Germany in Immuno-Oncology Collaboration -
Mar 29, 2021
F-star Therapeutics Reports Full-Year 2020 Financial Results and Provides Corporate Update -
Mar 16, 2021
F-star Therapeutics to Host Full-Year 2020 Investor Call and Provide Corporate Update on March 29, 2021 -
Mar 04, 2021
F-star Therapeutics to Present at Upcoming Investor Conferences -
Jan 20, 2021
F-star Granted Composition of Matter Patent for FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1 -
Jan 06, 2021
F-star Therapeutics to Participate in Upcoming Conferences -
Jan 04, 2021
F-star Therapeutics Announces First Patient Dosed in FS222 Phase 1 Clinical Trial -
Dec 03, 2020
F-star Therapeutics Announces First Patient Dosed in First-in-Class FS120 Phase 1 Clinical Trial -
Nov 24, 2020
F-star Therapeutics Announces Approval of Clinical Trial Application for FS222
Pagination
